Hyperfine Secures $40M Loan for Swoop System Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy HYPR?
Source: Yahoo Finance
- Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
- Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
- Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
- Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HYPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.030
Low
2.00
Averages
2.00
High
2.00
Current: 1.030
Low
2.00
Averages
2.00
High
2.00
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
Hyperfine Secures $40M Loan for Swoop System Expansion
- Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
- Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
- Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
- Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
See More
Horizon Grants $40 Million Loan Facility to Hyperfine, with $15 Million Disbursed at Closing
Loan Facility Announcement: Hyperfine Inc. has secured a $40 million loan facility to support its operations and growth.
Funding Details: The loan is backed by a $15 million funding commitment that was finalized at closing.
See More
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
See More
Hyperfine Inc Reports Strong Q4 Earnings with Significant Growth
- Significant Revenue Growth: Hyperfine Inc reported Q4 2025 revenue of $5.3 million, a 128% increase from the previous year, demonstrating strong performance in the next-generation Swoop scanner market and indicating potential for future sales growth.
- Gross Margin Expansion: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase year-over-year, highlighting successful cost control and pricing strategies that enhance its competitive position in the market.
- Reduced Cash Burn: Net cash burn for Q4 2025 was $5.7 million, down 30% year-over-year, reflecting improved financial discipline and operational efficiency, which is likely to boost investor confidence.
- Optimistic 2026 Outlook: Hyperfine anticipates 2026 revenue between $20 million and $22 million, representing a 55% growth at the midpoint, with gross margin guidance set at 50% to 55%, indicating a positive outlook on future market opportunities.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
Hyperfine Secures $40M Loan for Swoop System Expansion
- Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
- Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
- Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
- Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
See More
Horizon Grants $40 Million Loan Facility to Hyperfine, with $15 Million Disbursed at Closing
Loan Facility Announcement: Hyperfine Inc. has secured a $40 million loan facility to support its operations and growth.
Funding Details: The loan is backed by a $15 million funding commitment that was finalized at closing.
See More
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
See More
Hyperfine Inc Reports Strong Q4 Earnings with Significant Growth
- Significant Revenue Growth: Hyperfine Inc reported Q4 2025 revenue of $5.3 million, a 128% increase from the previous year, demonstrating strong performance in the next-generation Swoop scanner market and indicating potential for future sales growth.
- Gross Margin Expansion: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase year-over-year, highlighting successful cost control and pricing strategies that enhance its competitive position in the market.
- Reduced Cash Burn: Net cash burn for Q4 2025 was $5.7 million, down 30% year-over-year, reflecting improved financial discipline and operational efficiency, which is likely to boost investor confidence.
- Optimistic 2026 Outlook: Hyperfine anticipates 2026 revenue between $20 million and $22 million, representing a 55% growth at the midpoint, with gross margin guidance set at 50% to 55%, indicating a positive outlook on future market opportunities.
See More
